Drug Type Oncolytic virus |
Synonyms BI 1821736, BI1821736 |
Target |
Action agonists |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | United States | 07 Jun 2023 | |
Advanced cancer | Phase 1 | Canada | 07 Jun 2023 | |
Advanced cancer | Phase 1 | Spain | 07 Jun 2023 | |
Advanced cancer | Phase 1 | Sweden | 07 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 07 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 07 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Spain | 07 Jun 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Sweden | 07 Jun 2023 |